¹Ì±¹ÀÇ mRNA Ä¡·áÁ¦ °³¹ß ¹× Á¦Á¶ ¼öŹ ±â°ü ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ÀûÀÀÁõº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ºÎ¹® ¿¹Ãø(2025-2033³â)
U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Indication (Infectious Diseases, Metabolic & Genetic Diseases), By Application, By End Use, And Segment Forecasts, 2025 - 2033
»óǰÄÚµå : 1813823
¸®¼­Ä¡»ç : Grand View Research
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,443,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,862,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,700,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(ÀÚȸ»ç Æ÷ÇÔ)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹Ì±¹ÀÇ mRNA Ä¡·áÁ¦ CDMO½ÃÀå °³¿ä

¹Ì±¹ÀÇ mRNA Ä¡·áÁ¦ À§Å¹ °³¹ß ¹× Á¦Á¶ ±â°ü ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 14¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2033³â¿¡´Â 48¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 14.57%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀåÀ» ÁÖµµÇϰí ÀÖ´Â °ÍÀº »ý¸í°øÇÐ ±â¾÷ ¹× ¿¬±¸±â°üÀÇ Á¸Àç°¨, ±ÔÁ¦ ȯ°æÀÇ Á¤ºñÀÔ´Ï´Ù.

¶ÇÇÑ, ¹é½Å, ¾Ï Ä¡·á, Èñ±Í À¯ÀüÁúȯ¿¡ ´ëÇÑ mRNAÀÇ È°¿ë È®´ë°¡ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿©·¯ »ý¸í°øÇÐ ±â¾÷µéÀÌ mRNA ±â¹Ý Ä¡·áÁ¦ °³¹ß¿¡ Âü¿©Çϸ鼭 ºñ¿ë È¿À²¼º°ú ½ÃÀå Ãâ½Ã ±â°£ ´ÜÃàÀ» À§ÇØ Çö󽺹̵å DNA »ý»ê, ½ÃÇè°ü ³» Àü»ç(IVT), ÁöÁú ³ª³ëÀÔÀÚ(LNP) Á¦ÇüÈ­, ¹«±Õ ÃæÀü/¸¶¹«¸® µîÀÇ ¼­ºñ½º¸¦ °³¹ß ¹× Á¦Á¶ À§Å¹±â°ü¿¡ ÀÇ·ÚÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¡ ÀÇ·ÚÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÚµ¿È­, AI ±â¹Ý ǰÁú °ü¸®, ÷´Ü LNP ½Ã½ºÅÛ µî ½Å±â¼úÀÇ ÅëÇÕÀº »ý»ê ´É·ÂÀ» Çâ»ó½Ã۰í, °¡±î¿î ¹Ì·¡¿¡ ½ÃÀå ¼ºÀå ÀáÀç·ÂÀ» ³ôÀÏ °ÍÀÔ´Ï´Ù.

ÁÖ¿ä Á¦¾à»ç, »ý¸í°øÇÐ ±â¾÷, »ý¸í°úÇÐ ±â¾÷ÀÇ °­·ÂÇÑ Á¸Àç°¨ÀÌ ½ÃÀå ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ±íÀº °úÇÐÀû Àü¹® Áö½Ä, ÷´Ü ÀÎÇÁ¶ó, źźÇÑ ÀÚ±Ý Á¶´Þ »ýŰ踦 ¹ÙÅÁÀ¸·Î Áß±¹Àº ½Å¾à°³¹ß°ú Çõ½ÅÀÇ Áß½ÉÁö·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè, ƯÈ÷ Á¾¾çÇÐ, °¨¿°¼º Áúȯ, Èñ±Í À¯Àü¼º Áúȯ¿¡ ´ëÇÑ mRNA ±â¹Ý Ä¡·áÁ¦¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ À¯¿¬Çϰí È®Àå °¡´ÉÇÑ °³¹ß ¹× Á¦Á¶ À§Å¹ ±â°ü ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ì¾ÆÀÖ´Â »ý¼öó¸®Á¦ ¹× Â÷¼¼´ë »ý¹°ÇÐÀû Á¦Á¦ÀÇ ±â¼ú Çõ½ÅÀÌ ÁøÇàµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ƯÈ÷ Ä¡·á ºÒ°¡´ÉÇÑ Áúº´À̳ª Èñ±ÍÁúȯÀ» Ÿ°ÙÀ¸·Î ÇÏ´Â °æ¿ì ƯÈ÷ °ü·Ã¼ºÀÌ ³ôÀ¸¸ç, mRNA ÇÕ¼º, ÁöÁú³ª³ëÀÔÀÚ(LNP) Á¦ÇüÈ­, ¹«±Õ ÃæÀü/¸¶¹«¸® ±â´ÉÀ» °®Ãá °³¹ß ¹× Á¦Á¶ À§Å¹±â°ü¿¡ Å« ¾Æ¿ô¼Ò½Ì ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹ FDA¿Í °°Àº ±â°üÀÌ ÁÖµµÇÏ´Â È®¸³µÈ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â °³¹ß ÀÏÁ¤À» ¾Õ´ç±â°í, ȹ±âÀûÀÎ Ä¡·áÁ¦ÀÇ ½ÂÀÎ ¹× ½ÂÀΠȹµæÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù.

¶ÇÇÑ, ¹Ì±¹ FDA¿Í °°Àº È®¸³µÈ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â °³¹ß ÀÏÁ¤ÀÇ °¡¼ÓÈ­, ȹ±âÀû Ä¡·áÁ¦ ¹× ÆÐ½ºÆ®Æ®·¢ ÁöÁ¤À» ÅëÇÑ ½ÂÀÎ, GMP Áؼö¸¦ À§ÇÑ ¸íÈ®ÇÑ °æ·Î¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌó·³ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø Á¤Ã¥°ú Á¤ºÎÀÇ ÀÚ±Ý Áö¿øÀº ¿¹»ó ±â°£ µ¿¾È ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¹Ì±¹ÀÇ mRNA Ä¡·áÁ¦ À§Å¹ °³¹ß ¹× Á¦Á¶ ±â°ü ½ÃÀå ¼¼ºÐÈ­

ÀÌ º¸°í¼­´Â 2021³âºÎÅÍ 2033³â±îÁö ±¹°¡º° ¸ÅÃâ ¼ºÀåÀ» ¿¹ÃøÇϰí, °¢ ÇÏÀ§ ºÎ¹®ÀÇ ÃֽŠ»ê¾÷ µ¿Çâ¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. Grand View Research´Â ¹Ì±¹ÀÇ mRNA Ä¡·áÁ¦ À§Å¹ °³¹ß ¹× Á¦Á¶ ±â°ü ½ÃÀå º¸°í¼­¸¦ ÀûÀÀÁõ, ¿ëµµ, ÃÖÁ¾ ¿ëµµ¿¡ µû¶ó ¼¼ºÐÈ­ÇÏ¿© Á¶»çÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¹Ì±¹ÀÇ mRNA Ä¡·áÁ¦ °³¹ß ¹× Á¦Á¶ ¼öŹ ±â°ü ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¹Ì±¹ÀÇ mRNA Ä¡·áÁ¦ °³¹ß ¹× Á¦Á¶ ¼öŹ ±â°ü ½ÃÀå : ÀûÀÀÁõ ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦5Àå ¹Ì±¹ÀÇ mRNA Ä¡·áÁ¦ °³¹ß Á¦Á¶ ¼öŹ ±â°ü ½ÃÀå : ¿ëµµ ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦6Àå ¹Ì±¹ÀÇ mRNA Ä¡·áÁ¦ °³¹ß Á¦Á¶ ¼öŹ ±â°ü ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤ ¹× µ¿Ç⠺м®

Á¦7Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

U.S. mRNA Therapeutics CDMO Market Summary

The U.S. mRNA therapeutics contract development & manufacturing organization market size was estimated at USD 1.43 billion in 2024 and is projected to reach USD 4.85 billion by 2033, growing at a CAGR of 14.57% from 2025 to 2033. The market is driven by strong presence of biotech companies, research institutions, and a supportive regulatory environment.

Moreover, expanding usage of mRNA in vaccines, cancer treatments, and rare genetic diseases is expected to boost the market growth. As several biotech companies are involved in the development of mRNA-based therapeutics, these companies are increasingly turning to CDMOs for services such as plasmid DNA production, in vitro transcription (IVT), lipid nanoparticle (LNP) formulation, and aseptic fill/finish for cost-effectiveness and reduced time to market. In addition, integration of novel technologies such as automation, AI-based quality control, and advanced LNP systems boosts production capabilities, thereby driving the market growth potential in the near future.

The strong presence of leading pharmaceutical, biotechnology, and life sciences companies drives the demand in the market. The country remains a central drug discovery and innovation hub, supported by deep scientific expertise, advanced infrastructure, and robust funding ecosystems. The growing interest in clinical trials, particularly for mRNA-based therapeutics across oncology, infectious diseases, and rare genetic conditions, is propelling the demand for flexible and scalable CDMO services. Besides, increasing innovation of live biotherapeutics and next-generation biologics is expected to drive the market growth. These advancements are especially relevant in targeting previously untreatable or rare diseases, creating substantial outsourcing opportunities for CDMOs equipped with mRNA synthesis, lipid nanoparticle (LNP) formulation, and aseptic fill/finish capabilities. Furthermore, the well-established regulatory framework led by agencies such as the U.S. FDA facilitates accelerated development timelines, a

pprovals through breakthrough therapy and fast-track designations, and a clear path for GMP compliance. Thus, supportive regulatory policies and government funding are anticipated to drive the market over the estimated time period.

U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. mRNA therapeutics contract development & manufacturing organization market report based on indication, application, and end use.

Table of Contents

Chapter 1. Research Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Variables, Trends & Scope

Chapter 4. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market: Indication Estimates & Trend Analysis

Chapter 5. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market: Application Estimates & Trend Analysis

Chapter 6. U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market: End Use Estimates & Trend Analysis

Chapter 7. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â